Arlevert (cinnarizine, dimengidrinat) tablets №20

Arlevert (cinnarizine, dimenhydrinate) tablets №20

$18.00

Manufacturer: Germany

Dimenhydrinate, the chlortheophylline salt of diphenhydramine, acts as an antihistamine with anticholinergic (M-anticholinergic) activity, has a parasympatholytic effect and a depressant effect on the central nervous system. By acting on the chemoreceptor trigger zone in the 4th ventricle, dimenhydrinate suppresses the urge to vomit and dizziness. So, dimenhydrinate affects mainly the central vestibular system.

Due to its ability to block calcium receptors, cinnarizine inhibits the entry of calcium into the vestibular sensory cells, thereby acting as a vestibulolytic agent. Thus, cinnarizine mainly affects the peripheral vestibular system.

Category:

Description

Ingredients

active ingredients: cinnarizine; dimenhydrinate;

1 tablet contains cinnarizine 20 mg and dimenhydrinate 40 mg;

excipients : microcrystalline cellulose, corn starch, talc, hypromellose, colloidal silicon dioxide, magnesium stearate, croscarmellose sodium .

Dosage form

Pills.

Basic physical and chemical properties: tablets from white to pale yellow color with “A” embossed on one side.

Pharmacotherapeutic group

Drugs acting on the nervous system. Combination drug cinnarizine.

ATX code N07C A52.

Pharmacodynamics

Dimenhydrinate, the chlortheophylline salt of diphenhydramine, acts as an antihistamine with anticholinergic (M-anticholinergic) activity, has a parasympatholytic effect and a depressant effect on the central nervous system. By acting on the chemoreceptor trigger zone in the 4th ventricle, dimenhydrinate suppresses the urge to vomit and dizziness. So, dimenhydrinate affects mainly the central vestibular system.

Due to its ability to block calcium receptors, cinnarizine inhibits the entry of calcium into the vestibular sensory cells, thereby acting as a vestibulolytic agent. Thus, cinnarizine mainly affects the peripheral vestibular system.

Both cinnarizine and dimenhydrinate are known agents for the treatment of vertigo. According to the test results, the combined agent for its effectiveness exceeds each of its components separately. As a remedy for motion sickness, this drug has not been studied.

Indications

Symptomatic treatment of dizziness of various origins. Arlevert (cinnarizine, dimenhydrinate) is indicated for adult patients.

Contraindications

Allergic reactions to the active ingredients, diphenhydramine or other antihistamines of a similar structure, or to any excipient.

Diphenhydramine is excreted exclusively by the kidneys, so patients with severe renal insufficiency were excluded from the clinical development program. Arlevert® should not be used in patients with severe renal impairment (creatinine clearance £ 25 ml/min).

Since both active ingredients of the drug Arlevert® are extensively metabolized by hepatic enzymes of the cytochrome P450 system, in patients with severely impaired liver function, plasma concentrations of the active substances (unchanged) and their half-life increase. With respect to diphenhydramine, this has been shown in patients with cirrhosis of the liver. Therefore, Arlevert® should not be used in patients with severe hepatic impairment.

Arlevert (cinnarizine, dimenhydrinate) should not be used in patients with angle-closure glaucoma, seizures, suspected increased intracranial pressure, as well as in patients with alcoholism, urinary retention caused by disorders of the urethra and prostate gland.

Dosage and administration

Adults. 1 tablet 3 times a day after meals, without chewing, with a small amount of liquid.

Elderly patients. Dose adjustment is not required.

Impaired kidney function. Patients with mild to moderate renal impairment should use Arlevert (cinnarizine, dimenhydrinate) with caution. Arlevert® should not be used in patients with a creatinine clearance of £25 ml/min (severe renal impairment).

Impaired liver function. Studies of the use of the drug in patients with impaired liver function have not been conducted. Patients with severe hepatic insufficiency should not use Arlevert (cinnarizine, dimenhydrinate).

The duration of the treatment should not exceed 4 weeks. The decision on longer treatment should be made by the doctor.

Related products